IQVIA Biotech Thought Leadership
-
Achieving Excellence In IO Clinical Trials
6/21/2023
Immuno-oncology therapies have revolutionized the treatment of cancer patients worldwide. Learn how to plan for success and reduce risk when developing novel treatments for patients with cancer.
-
DLBCL Asia-Pacific Insights And Experiences
6/21/2023
Get an overview of trends and insights into the current development of DLBCL clinical trials in the APAC and excerpts from an expert panel discussion from eight APAC countries.
-
Unlocking Europe's Commercial Potential For Biopharma Startups
6/21/2023
Dive into this compelling case for launching emerging biopharma in Europe and how to succeed.
-
Mitigating CAR Risks In Autologous CAR-T Therapy Trials In Oncology
6/21/2023
Developed from a clinical trial perspective, consider these practices when managing toxicities associated with autologous CAR-T therapies among patients with B-cell hematologic malignancies.
-
The Shifting Paradigm Of Dose Selection In Oncology
6/21/2023
Oncology drug development is undergoing a significant transformation. Explore strategies for integrating dose finding and optimization into early clinical development and how it could benefit oncology patients.
-
Navigating An Evolving Global Regulatory Landscape
8/19/2021
Our regulatory experts are closely following the evolution of regulatory guidance on COVID-19 and the approach taken by global regulatory agencies.
-
Nuances Of Hematologic Oncology Clinical Trials
7/26/2021
This paper examines the requirements for effectively and successfully conducting hematologic oncology clinical trials.
-
Going Virtual: Yes, Oncology Trials Can Do It Too
8/19/2021
How do patients receive necessary continued care when there is limited or no access to providers or trial sites? With the risk of exposure to COVID-19, will immunocompromised patients be safe to participate in trials in the traditional sense now and in the future?
-
Natural History Studies For Rare Diseases: Development Strategies For External Comparator Arms Leveraging Real World Insights
7/26/2021
This paper explores essential principles for defining the right strategy for natural history studies and how to design such studies in a way that the data can be used as an external comparator to augment future regulatory filings and payer submissions.
-
Partnering Solutions For Emerging Biopharma
7/26/2021
This paper is the first part of a series of articles aimed at helping the EBP team better assess the value of a “partnered” outsourcing approach across the continuum of development and commercialization, and potential approaches to mapping out the right fit for their organizational needs.